Company intelligence / Profile preview
Tianjin Fusogen Pharmaceuticals
Tianjin, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Tianjin Fusogen Pharmaceuticals is a Chinese biotech company focused on developing anti-HIV therapeutics. Its lead candidate, Sifuvirtide, is a synthetic peptide HIV fusion inhibitor targeting gp41. Sifuvirtide entered Phase 2 clinical trials in July 2006 and was developed with support from China’s national 863 Program. The company has at least three anti-HIV products in its pipeline. Clinical results for Sifuvirtide have not been widely published; the drug was designed to offer a lower-cost alternative to first-generation fusion inhibitors like T20/enfuvirtide.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Synthetic peptideSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Supported by China’s national “863 Program” for high-tech R&D funding
Beyond the preview
Go deeper on Tianjin Fusogen Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tianjin Fusogen Pharmaceuticals.